Clinical Trials
44 trialsNCT04960709 2026-06-04
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT04269200 2026-06-01
DUO-E
AstraZeneca
Phase 3 Active not recruiting
NCT04092283 2026-05-29
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03682068 2026-05-28
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT03875235 2026-05-26
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
NCT05943106 2026-05-26
PATAPSCO
AstraZeneca
Phase 3 Active not recruiting
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT05221840 2026-05-18
PACIFIC-9
AstraZeneca
Phase 3 Active not recruiting
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03706690 2026-05-13
PACIFIC-5
AstraZeneca
Phase 3 Active not recruiting
NCT04550260 2026-05-13
KUNLUN
AstraZeneca
Phase 3 Active not recruiting
NCT06732401 2026-05-13
CLEAR
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02453282 2026-05-12
MYSTIC
AstraZeneca
Phase 3 Active not recruiting
NCT04116047 2026-05-07
CompARE
University of Birmingham
Phase 3 Active not recruiting
NCT05170204 2026-05-06
HORIZON 1
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05883644 2026-04-30
SIERRA
AstraZeneca
Phase 3 Active not recruiting
NCT03833154 2026-04-23
PACIFIC-4
AstraZeneca
Phase 3 Active not recruiting
NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT05687266 2026-04-22
AVANZAR
AstraZeneca
Phase 3 Active not recruiting
NCT05771480 2026-04-21
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT02516241 2026-04-20
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT06746116 2026-04-16
DUoENDE
AstraZeneca
Phase 3 Active not recruiting
NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT03528694 2026-04-14
POTOMAC
AstraZeneca
Phase 3 Active not recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT06112379 2026-04-02
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT04637594 2026-03-20
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT05629585 2026-03-18
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
AstraZeneca
Phase 3 Active not recruiting
NCT03164616 2026-03-13
POSEIDON
AstraZeneca
Phase 3 Active not recruiting
NCT03732677 2026-03-13
NIAGARA
AstraZeneca
Phase 3 Active not recruiting
NCT03003962 2026-03-11
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
Phase 3 Active not recruiting
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT04592913 2025-12-24
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT06211036 2025-12-17
DeLLphi-305
Amgen
Phase 3 Active not recruiting
NCT03703297 2025-11-21
ADRIATIC
AstraZeneca
Phase 3 Active not recruiting
NCT03519971 2025-10-28
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT02273375 2025-08-12
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Canadian Cancer Trials Group
Phase 3 Active not recruiting
NCT05298423 2025-08-01
KEYVIBE-006
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03800134 2025-06-11
AEGEAN
AstraZeneca
Phase 3 Active not recruiting
NCT03737643 2025-01-29
DUO-O
AstraZeneca
Phase 3 Active not recruiting
NCT04597671 2025-01-29
NVALT28
Dutch Society of Physicians for Pulmonology and Tuberculosis
Phase 3 Active not recruiting